{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:27:35Z","timestamp":1792056455576,"version":"4.4.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:00:00Z","timestamp":1725580800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.rpth.2024.102571","type":"journal-article","created":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T21:27:52Z","timestamp":1726176472000},"page":"102571","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Multiple myeloma: retrospective assessment of routine thromboprophylaxis and utility of thrombotic risk scores"],"prefix":"10.1016","volume":"8","author":[{"given":"Omar Eduardo","family":"Fernandez-Vargas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Amezcua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Cabello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Quintana Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramiro","family":"Espinoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Cesarman-Maus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2024.102571_bib1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.rpth.2024.102571_bib2","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1182\/blood-2008-04-151076","article-title":"Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma","volume":"112","author":"Kristinsson","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102571_bib3","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1200\/JCO.2010.31.6844","article-title":"Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial","volume":"29","author":"Palumbo","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.rpth.2024.102571_bib4","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/bjh.17772","article-title":"Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis","volume":"196","author":"Piedra","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2024.102571_bib5","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1182\/blood-2011-03-344333","article-title":"Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide","volume":"119","author":"Larocca","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102571_bib6","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/bjh.16653","article-title":"Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents","volume":"190","author":"Cornell","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2024.102571_bib7","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3390\/cancers12010191","article-title":"Multiple myeloma and thrombosis: prophylaxis and risk prediction tools","volume":"12","author":"Fotiou","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.rpth.2024.102571_bib8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.rpth.2024.102571_bib9","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.clml.2011.03.006","article-title":"Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide\/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens","volume":"11","author":"Zangari","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.rpth.2024.102571_bib10","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1200\/JCO.2013.48.7934","article-title":"International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation","volume":"32","author":"Palumbo","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.rpth.2024.102571_bib11","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1111\/bjh.17505","article-title":"Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: a retrospective cohort study","volume":"193","author":"Covut","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2024.102571_bib12","doi-asserted-by":"crossref","first-page":"840","DOI":"10.6004\/jnccn.2018.7273","article-title":"Derivation and validation of a risk assessment model for immunomodulatory drug\u2013associated thrombosis among patients with multiple myeloma","volume":"17","author":"Li","year":"2019","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.rpth.2024.102571_bib13","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1182\/blood.2022015727","article-title":"Abnormal metaphase cytogenetics predicts venous thromboembolism in myeloma: derivation and validation of the PRISM score","volume":"140","author":"Chakraborty","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102571_bib14","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.3324\/haematol.2014.117176","article-title":"European Myeloma Network Guidelines for the management of multiple myeloma-related complications","volume":"100","author":"Terpos","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.rpth.2024.102571_bib15","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer","volume":"5","author":"Lyman","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2024.102571_bib16","first-page":"47","article-title":"Oncogu\u00eda de trombosis venosa asociada a c\u00e1ncer: profilaxis y tratamiento 2023","volume":"5","author":"Fern\u00e1ndez Vargas","year":"2023","journal-title":"Lat Am J Clin Sci Med Technol"},{"key":"10.1016\/j.rpth.2024.102571_bib17","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/ajh.25459","article-title":"Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study","volume":"94","author":"Pegourie","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.rpth.2024.102571_bib18","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.3324\/haematol.2022.280893","article-title":"Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an ad hoc expert panel","volume":"107","author":"De Stefano","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.rpth.2024.102571_bib19","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.thromres.2023.11.021","article-title":"Venous thromboembolism prophylaxis and multiple myeloma patients in real-life: results of a large survey and clinical guidance recommendations from the IFM group","volume":"233","author":"Frenzel","year":"2024","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2024.102571_bib20","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/bjh.19017","article-title":"Direct oral anticoagulants versus aspirin for primary thromboprophylaxis in patients with multiple myeloma undergoing outpatient therapy: a systematic review and updated meta-analysis","volume":"203","author":"Costa","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2024.102571_bib21","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1080\/10428194.2020.1804558","article-title":"Different outcomes for transplant-eligible newly diagnosed multiple myeloma patients in Latin America according to the public versus private management: a GELAMM study","volume":"61","author":"Pe\u00f1a","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.rpth.2024.102571_bib22","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/bjh.16124","article-title":"Multiple myeloma treatment patterns and clinical outcomes in the Latin America Haemato-Oncology (HOLA) observational study, 2008\u20132016","volume":"188","author":"de Moraes Hungria","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2024.102571_bib23","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102571_bib24","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/cam4.1927","article-title":"Application of risk factors for venous thromboembolism in patients with multiple myeloma starting chemotherapy, a real-world evaluation","volume":"8","author":"Baker","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.rpth.2024.102571_bib25","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1182\/blood.2020005125","article-title":"Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials","volume":"136","author":"Bradbury","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102571_bib26","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/bjh.18432","article-title":"Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: analysis of vascular thrombotic events in the GRIFFIN study","volume":"199","author":"Sborov","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2024.102571_bib27","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/MCP.0b013e3281eb8ef0","article-title":"The effects of race\/ethnicity and sex on the risk of venous thromboembolism","volume":"13","author":"Keenan","year":"2007","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.rpth.2024.102571_bib28","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12634","article-title":"Evaluation of the Khorana score for prediction of venous thromboembolism in patients with multiple myeloma","volume":"6","author":"Sanfilippo","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102571_bib29","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1007\/s11239-021-02407-5","article-title":"Heparin versus aspirin thromboprophylaxis adds independent value to IMPEDE-VTE score for venous thrombosis prediction in multiple myeloma","volume":"52","author":"Bravo-Perez","year":"2021","journal-title":"J\u00a0Thromb Thrombolysis"},{"key":"10.1016\/j.rpth.2024.102571_bib30","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.clml.2020.11.015","article-title":"Thromboembolism incidence and risk factors in multiple myeloma after first exposure to immunomodulatory drug\u2013based regimens","volume":"21","author":"Patel","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.rpth.2024.102571_bib31","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1182\/bloodadvances.2019001275","article-title":"Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma","volume":"4","author":"Mellors","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2024.102571_bib32","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/sj.bmt.1701943","article-title":"Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma","volume":"24","author":"Rajkumar","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.rpth.2024.102571_bib33","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1182\/blood-2023-182926","article-title":"External validation of PRISM score in multiple myeloma patients in a community setting: a retrospective cohort study","volume":"142","author":"Sekar","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102571_bib34","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1002\/rth2.12411","article-title":"Venous thromboembolism in multiple myeloma is associated with increased mortality","volume":"4","author":"Schoen","year":"2020","journal-title":"Res Pract Thromb Haemost"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037924002668?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037924002668?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T19:22:39Z","timestamp":1732216959000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037924002668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S2475037924002668"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2024.102571","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multiple myeloma: retrospective assessment of routine thromboprophylaxis and utility of thrombotic risk scores","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2024.102571","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"102571"}}